|
 Molecular Partners will get an upfront payment of 60 million Swiss
francs ($66.2 million), a potential milestone payment of 150 million
francs, and a "significant royalty" on sales of the drugs called
MP0420 and MP0423.
Molecular Partners' shares rose more than 32% before paring gains to
about 20% at 0950 GMT, reducing their year-to-date drop, set into
motion in large part by an eye drug that failed to win regulators'
blessing, to 12%.
Novartis shares fell 1.7%, continuing their slide from Tuesday after
third-quarter sales missed expectations.
First human studies for MP0420 are expected to start in November,
Molecular Partners has said, with clinical studies for MP0423 due to
begin in the first half of 2021.
Molecular Partners struck a deal with the Swiss government in August
to reserve doses of MP0420.
"It has become increasingly clear that to tackle the pandemic at a
global level the development of medicines that can prevent and treat
the virus, in addition to the development of vaccines, will be
crucial," Novartis said.
[to top of second column] |
Novartis's efforts to combat COVID-19 have focused largely on repurposing older
medicines, including its malaria drug hydroxychloroquine that won U.S. President
Donald Trump's endorsement but flopped in trials.
Novartis does have its own COVID-19 drug-discovery programme, but with a pair of
prospective medicines due to enter the clinic only next year, the Molecular
Partners deal could help speed up entry into the field.
Molecular Partners is seeking to regain its lustre after its eye drug abicipar,
in a partnership with U.S. drugmaker AbbVie, failed to win U.S. Food and Drug
Administration approval.
($1 = 0.9070 Swiss francs)
(Reporting by John Miller; Editing by Michael Shields and Mark Potter)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
